Veterinary Parasiticide Felpreva® (tigolaner / emodepside / praziquantel) Receives Positive Opinion From European Committee for Medicinal Products for Veterinary Use (CVMP)
Vetoquinol (Paris: VETO) today announced that the European Medicines Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) has adopted a positive opinion recommending the granting of a marketing authorization of Felpreva® spot-on solution (tigolaner, emodepside, praziquantel). Felpreva® is proposed to treat endoparasite infestations, as well as for treatment and control of ectoparasites in cats.1
Felpreva® is a fixed combination product in the form of a spot-on parasiticide solution for the treatment of cats when ectoparasites, cestodes and nematodes are targeted at the same time.1
“We are delighted to receive this positive opinion from the CVMP for Felpreva® for the treatment and prevention of fleas, worms, ticks and mites in cats. The parasiticide market is one of Vetoquinol’s key strategic therapy areas and today’s milestone marks Vetoquinol’s ongoing commitment to this essential category of veterinary medicines,” said Matthieu Frenchin, CEO of Vetoquinol.
Following an anticipated positive decision from the European Medicines Agency on Vetoquinol’s application for marketing authorization of Felpreva®, the veterinary medicinal product is expected to be available to veterinarians across Europe in 2022.
For any specific enquiries about Felpreva®, please email: email@example.com
1 EMA Summary of Positive Opinion – Felpreva. 2021. Available from: https://www.ema.europa.eu/en/
medicines/veterinary/summaries-opinion/felpreva [Accessed 10 September 2021].
Vetoquinol is a leading global animal health company committed to delivering breakthrough therapies that improve the lives of animals and support the diverse needs of veterinarians around the world.
With a range of successful and trusted veterinary parasiticide products, Vetoquinol has rapidly become an important player in the global companion animal veterinary parasiticides market.
As an independent family-owned company, focussed on veterinary medicines, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has been focussed on creating strong mutually beneficial partnerships with veterinary professionals, building a genuine relationship of trust with its customers, in line with its mission to “achieve more together”.
Vetoquinol employed 2,525 people as of June 30th , 2021.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).
For further information, go to: www.vetoquinol.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-LANDMARK-WORLDWIDE16.9.2021 20:02:03 CEST | Press release
Landmark Celebrates 30 Years as the Industry Leader in Personal & Professional Growth, Training and Development
IL-ISACA16.9.2021 19:23:08 CEST | Press release
ISACA to Host Inaugural ISACA Conference Europe Virtual Event
PA-VIRPAX-PHARMA16.9.2021 19:02:07 CEST | Press release
Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock
CA-VERIMATRIX16.9.2021 17:47:13 CEST | Press release
Verimatrix To Highlight Success In Enabling Secure Virtual Hollywood Events at Variety Entertainment & Technology Summit
FL-EXACTECH16.9.2021 16:08:13 CEST | Press release
Exactech’s Equinoxe® Stemless Shoulder Replacement System Debuts in Europe
BOEHRINGER-INGELHEIM16.9.2021 14:02:08 CEST | Press release
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
TX-SOFTSERVE16.9.2021 13:07:11 CEST | Press release
SoftServe Wins Gold in 2021 Brandon Hall Group Excellence in Leadership Development Awards
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom